Novel therapies to reduce the progressive and destructive nature of inflammatory joint disease are always welcome, provided that safety is not compromised. Among the many 2015 studies in the field, we highlight a targetable mechanism of uric-acid-induced inflammation in gouty arthritis and the expected efficacy — but unforeseen safety concerns — of anti-IL-17 antibodies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Molecular basis for the recognition of 24-(S)-hydroxycholesterol by integrin αvβ3
Scientific Reports Open Access 06 June 2023
-
Anti-inflammatory Effects and Mechanisms of Rhein, an Anthraquinone Compound, and Its Applications in Treating Arthritis: A Review
Natural Products and Bioprospecting Open Access 30 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Frenzel, E. et al. Acute-phase protein α1-antitrypsin — a novel regulator of angiopoietin-like protein 4 transcription and secretion. J. Immunol. 192, 5354–5362 (2014).
Joosten, L. A. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237–3248 (2010).
Joosten, L. A. et al. α-1-anti-trypsin–Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-206966 (2015).
Abbate, A. et al. Effects of Prolastin C (plasma-derived α-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-α 1-RT pilot study). Am. J. Cardiol. 115, 8–12 (2015).
Crisan, T. O. et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-206564 (2015).
Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426–2437 (2009).
Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329–1339 (2015).
McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 386, 1137–1146 (2015).
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
Colombel, J. F., Sendid, B., Jouault, T. & Poulain, D. Secukinumab failure in Crohn's disease: the yeast connection? Gut 62, 800–801 (2013).
Acknowledgements
The authors acknowledge support from the NIH (Grant AI 15614 to C.A.D.) and the Interleukin Foundation and the Dutch Arthritis Association (Grant NR-12-2-303 to L.A.B.J.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dinarello, C., Joosten, L. New tools to tackle inflammatory arthritis. Nat Rev Rheumatol 12, 78–80 (2016). https://doi.org/10.1038/nrrheum.2015.180
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.180
This article is cited by
-
Molecular basis for the recognition of 24-(S)-hydroxycholesterol by integrin αvβ3
Scientific Reports (2023)
-
Anti-inflammatory Effects and Mechanisms of Rhein, an Anthraquinone Compound, and Its Applications in Treating Arthritis: A Review
Natural Products and Bioprospecting (2020)
